Capricor Therapeutics Faces Class Action Lawsuits Over Alleged Misleading Drug Development Statements

### Capricor Therapeutics Faces Class Action Lawsuits Over Alleged Misleading Statements

Capricor Therapeutics, Inc. is currently embroiled in multiple class action lawsuits filed by law firms alleging violations of the Securities Exchange Act of 1934. These lawsuits stem from claims that the company made misleading statements about its drug candidate, deramiocel, during a critical phase of development. Specifically, the suits focus on allegations that Capricor misrepresented the progress of its drug towards FDA approval, asserting that the company concealed adverse data from its Phase 2 HOPE-2 trial. The class period for these lawsuits spans from October 9, 2024, to July 10, 2025, with a deadline for affected shareholders to participate set for September 15, 2025.

The lawsuits assert that Capricor's claims regarding a successful mid-cycle review and plans for an advisory committee meeting were misleading. Investors allege that the company knew about concerning data from the HOPE-2 trial but failed to disclose this information, thereby creating a false impression of the drug's potential for approval. As the truth about the drug's safety and efficacy emerged, investors reportedly suffered significant financial losses. The law firms involved, including Schall Law Firm and DJS Law Group, are actively seeking affected shareholders to join the class action lawsuits, highlighting that participation can provide a pathway to recover damages incurred during the specified period.

The legal landscape for Capricor is complex as shareholders consider their options amidst these lawsuits. While the class actions are pending certification, the firms emphasize the importance of acting promptly to secure representation. They offer various resources, including free consultations and monitoring services for investors. These developments underscore the ongoing scrutiny Capricor faces as it navigates the regulatory and market challenges associated with its leading cell therapy for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). The implications of these lawsuits could have far-reaching effects on Capricor's reputation and future endeavors in the biopharmaceutical industry.

In addition to the ongoing class actions, the Rosen Law Firm has cautioned investors about the importance of selecting experienced legal counsel for securities class actions. The firm has a history of significant settlements and encourages potential lead plaintiffs to act before the looming deadline. Meanwhile, the DJS Law Group emphasizes their commitment to advocating for investor rights, aiming to enhance returns through robust legal support. As these lawsuits progress, Capricor's future and the fate of its drug candidate remain uncertain, highlighting the critical intersection of innovation and regulatory compliance in the biopharmaceutical sector.